A consultant who has analyzed healthcare policy over many decades declares that MA is in the middle of a fundamental reset ...

Healthcare industry business strategy is at a crossroads. More than ever, driving revenue is front and center in discussions among hospital and health system executives. Too often, however, those ...

Obsidian Therapeutics is merging with Galera Therapeutics to advance clinical development of a pipeline led by a next-generation cell therapy for melanoma that could offer advantages over the only ...

This month, the Centers for Medicare & Medicaid Services announced the first wave of tools and partnerships under its Health Tech Ecosystem initiative — including the novel Medicare App Library — ...

In a cell, the nucleus and related genetic material are housed inside a double-layered membrane. Scientists previously thought this nuclear envelope played a passive role, simply separating these ...

Most of what we called healthcare innovation over the last decade was an expensive lie we told ourselves. Between 2015 and 2020, we poured billions into digitizing the status quo, making existing ...

Industry leaders say the No Surprises Act is protecting patients from surprise bills, but its Independent Dispute Resolution system is being overused and exploited, driving up costs and prompting ...

Rep. Greg Murphy (R-North Carolina) introduced the Every Dollar Counts Act on Tuesday. It would ensure out-of-pocket costs for covered prescription drugs are applied toward patients’ deductibles and ...

The Peterson Health Technology Institute will function as an “independent evaluator” of digital health solutions. It will analyze solutions' clinical effectiveness, how they’re affecting healthcare ...

Healthcare AI company Innovaccer announced on Wednesday that it is committing $250 million over the next three years to build out its platform of AI agents, which perform tasks across five main ...

HeartFlow, which makes AI tools to analyze cardiac images, sued its rival Cleerly, alleging infringement on six patents. Cleerly is pushing back.

The journey of a Travere Therapeutics drug has culminated in a long-awaited FDA approval, making the once-daily pill the first therapy for a rare disease that, in severe cases, leads to kidney failure ...